BiotechTube

ONO-2506 + ONO-2506 + ONO-2506

Phase 2/3Completed
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stroke

Conditions

Stroke

Trial Timeline

Sep 1, 2005 → Sep 1, 2008

NCT ID
NCT00229177

About ONO-2506 + ONO-2506 + ONO-2506

ONO-2506 + ONO-2506 + ONO-2506 is a phase 2/3 stage product being developed by Ono Pharmaceutical for Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT00229177. Target conditions include Stroke.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT00229177Phase 2/3Completed

Competing Products

20 competing products in Stroke

See all competitors
ProductCompanyStageHype Score
SPT-07A injectionSinopharmPhase 3
76
Osmotic drugsSinopharmPre-clinical
22
Aspirin, ClopidogrelYuhanPre-clinical
23
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
41
SUN13837 + placeboDaiichi SankyoPhase 2
52
DS-1040b + AspirinDaiichi SankyoPhase 1
33
piclozotan low dose + placebo + piclozotan high doseDaiichi SankyoPhase 2
52
DS1040b + PlaceboDaiichi SankyoPre-clinical
23
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
52
warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxabanDaiichi SankyoPhase 3
77
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
52
ASP2246Astellas PharmaPhase 1/2
41
Neu2000KWL + Neu2000KWL + Neu2000KWL + PlacebosSun PharmaceuticalPhase 2
52
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
52
Redasemtide + PlaceboShionogiPhase 2
52
StatinShionogiApproved
85
AlteplaseKyowa KirinApproved
85
AbciximabEli LillyPhase 3
77
AbciximabEli LillyPhase 3
77
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
52

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved
85
Abatacept + Placebo matching with Abatacept + MethotrexateApproved
85
Rivastigmine transdermal patchApproved
85
Sitagliptin phosphatePhase 3
77
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3
77